Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of SP-104 vs Naltrexone in Healthy Adults
NCT05002946Phase 1Completed
- Sponsor
- Scilex Holding
- Start
- Jan 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of naltrexone hydrochloride delayed-release in fibromyalgia (FM) (3 arms), sponsored by Scilex Holding. Primary endpoints: Concentration of SP-104 at 72 hours and Time to maximum concentration of naltrexone and metabolite 6β-naltrexol at 72 hours. Started Jan 2022; status: completed.
02
Drugs
naltrexone hydrochloride delayed-release
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT05002946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05002946.